Gemtuzumab Ozogamicina

Resumen

Alternativas con registro en Colombia

• Edrecolomab
• Ipilimumab · costo anual estimado $ 1.144.599.485
• Brentuximab Vedotina
• Blinatumomab · costo anual estimado $ 575.343.295
• Enfortumab Vedotina
• Polatuzumab Vedotin · costo anual estimado $ 634.694.850
• Sacituzumab Govitecan · costo anual estimado $ 835.929.935
• Tremelimumab
• Tarlatamab

Estudios clínicos principales

• Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
  Fase 3 · 2006 · 1.070 participantes · Children's Oncology Group · NCT00372593 · PubMed 25092781
• A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
  Fase 3 · 2007 · 280 participantes · Acute Leukemia French Association · NCT00927498
• AML-19: Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
  Fase 2/3 · 2004 · 279 participantes · European Organisation for Research and Treatment of Cancer - · NCT00091234
• Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
  Fase 3 · 2002 · 657 participantes · Eastern Cooperative Oncology Group · NCT00049517 · PubMed 19776406 · PubMed 16996130

Enfermedades relacionadas

• Cáncer (todos)
• Leucemias

Fuentes

• Etiqueta FDA (DailyMed): Mylotarg
• EMA: Mylotarg